In this study, we investigated the effect of percutaneous transluminal coronary angioplasty (PTCA) on functional exercise capacity, oxygen uptake at anaerobic threshold (VO2AT) and maximal oxygen uptake (VO2max) in patients with coronary artery disease (CAD). Twenty-five patients with CAD and stable angina pectoris underwent spiroergometry before and after PTCA. All patients had reduced functional capacity with Weber class B in 5, class C in 16 and class D in 4 patients with mean VO2AT of 9.4 ± 1.5 ml·kg–1·min–1 and mean VO2max of 13.3 ± 3.3 ml· kg–1·min–1. After PTCA, VO2max (15.8 ± 3.1 ml·kg–1· min–1) increased significantly (p < 0.001) compared to before PTCA. Subgroup analysis revealed that patients with low functional capacity before PTCA (VO2max <15 ml· kg–1· min–1) had the most benefit from PTCA with an increase in VO2AT from 8.7 ± 1.0 to 9.6 ± 1.4 ml·kg–1· min–1 (p < 0.05) and of VO2max from 11.3 ± 2.2to 14.8 ± 3.5 ml·kg–1·min–1 (p < 0.001) whereas in patients with VO2max >15 ml·kg–1·min–1, VO2AT (p = 0.9) and VO2max (p = 0.2) did not improve significantly. In conclusion, there is reduced functional capacity and VO2max which improved after PTCA in CAD patients. In patients with low VO2max before PTCA, functional capacity, VO2AT and VO2max significantly improved after PTCA, suggesting reversible myocardial impairment induced by intermittent myocardial ischemia. Patients with higher VO2max had no significant benefit from PTCA with respect to functional capacity, VO2max and VO2AT.

Keywords:
Coronary artery disease, Exercise testing, Spiroergometry, Oxygen uptake, Anaerobic threshold, Percutaneous transluminal coronary angioplasty
1.
Kent KM, Bentivoglio LG, Block PC, Bourassa MG, Cowley MJ, Dorros G, Detre KM, Gosselin AJ, Gruentzig AR, Kelsey SF, Mock MB, Mullin SM, Passamani ER, Myler RK, Simpson J, Stertzer SH, Van Raden MJ, Williams DO: Long term efficacy of percutaneous transluminal coronary angioplasty: Report from the National Heart, Lung and Blood Institute PTCA Registry. Am J Cardiol 1984;53:27c.
2.
Berger E, Williams DO, Reinert S, Most AS: Sustained efficacy of percutaneous transluminal coronary angioplasty. Am Heart J 1986;111:233.
3.
Thomas ES, Most AS, Williams DO: Coronary angioplasty for patients with multivessel disease: Follow-up clinical status. Am Heart J 1988;115:8–13.
4.
Winter UJ, Gitt AK, Blaum M, Fritsch J, Berge PG, Pothoff G, Hilger HH: Cardio-pulmonary exercise capacity in patients with coronary heart disease. Z Kardiol 1994;83(suppl 3):73–82.
5.
Wassermann K, Hansen JE, Sue DY, Whipp BJ: Principles of Exercise Testing and Interpretation. Philadelphia, Lea & Febiger, 1987.
6.
Gibbons R, Balady G, Beasley J, Bricker J, Duvernoy W, Froelicher V, Mark D, Marwick T, McCallister B, Thompson P, Winters W: Exercise testing guidelines. J Am Coll Cardiol 1997;30:260–315.
7.
Beaver WL, Wassermann K, Whipp B: A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020–2027.
8.
Weber KT, Kinasewitz GT, Janicki JD, Fishman AP: Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation 1982;65:1213.
9.
Rentrop P, Friedrich B, Roskamm H: Hemodynamics at rest and during exercise depending on severity and localisation of coronary artery disease (in German). Med Klin 1975;70:1962–1965.
10.
Auchincloss JH, Gilbert R, Kuppinger M, Peppi D, Teperow-Putter K: One and three-minute exercise response in coronary artery disease. J Appl Physiol 1979;46:1132–1137.
11.
Fortini A, Bonechi F, Taddei T, Gensini GF, Malfanti PL, Neri Serneri GFG: Anaerobic threshold in patients with exercise-induced myocardial ischemia. Circulation 1991;83(5 suppl):III50–III53.
12.
Sigwart U, Grbic M, Payot M, et al: Ischemic events during coronary artery balloon obstruction; in Rutishauser W, Roskamm H (eds): Silent Myocardial Ischemia. Berlin, Springer, 1984, pp 29–36.
13.
Adachi H, Koike A, Niwa A, Sato A, Takamoto T, Marumo F, Hiroe M: Percutaneous transluminal coronary angioplasty improves oxygen uptake kinetics during the onset of exercise in patients with coronary artery disease. Chest 2000;118:329–335.
14.
Sax FL, Cannon RO III, Hanson C, Epstein SE: Impaired forearm vasodilatator reserve in patients with microvascular angina. N Engl J Med 1987;317:1366–1370.
15.
Karlsson J: Onset of blood lactate accumulation, exercise capacity, skeletal muscle fibres and metabolism before and after coronary artery bypass grafting. Am J Cardiol 1988;62:108E–114E.
16.
Mann T, Brodie B, Grossmann W: Effect of angina on the left ventricular diastolic pressure-volume relationship. Circulation 1977;55:761–766.
17.
Mann T, Goldberg S, Mudge G: Factors contributing to altered left ventricular diastolic properties during angina pectoris. Circulation 1979;59:14–18.
18.
Barry W, Brooker J, Alderman E: Changes in diastolic stiffness and tone of the left ventricle during angina pectoris. Circulation 1974;49:255–263.
19.
Bonow R, Kent K, Rosing D, Lipson L, Bacharach S, Green M, Epstein S: Improved left ventricular diastolic filling in patients with coronary artery disease after percutaneous transluminal coronary angioplasty. Circulation 1982;66:1159–1167.
20.
Carroll J, Hess O, Hirzel H: Left ventricular systolic and diastolic function in patients with coronary artery disease. Circulation 1985;72:119–129.
21.
Carroll JD, Carroll E: Diastolic function in coronary artery disease. Herz 1991;16:1–12.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.